Financial Performance Summary
CORONA Remedies Limited announced its unaudited financial results for the first quarter of FY27 (Q1FY27) ended June 30, 2026.
Key Financial Metrics (₹ in Crores):
| Particulars | Q1FY27 | Q1FY26 | Y-o-Y % Growth |
| Revenue from Operations | 422.4 | 346.5 | 21.9% |
| EBITDA | 93.1 | 69.8 | 33.5% |
| EBITDA Margin | 22.0% | 20.1% | 190 bps improvement |
| Profit After Tax | 60.1 | 46.2 | 30.1% |
| Profit After Tax Margin | 14.2% | 13.3% | 90 bps improvement |
Operational Highlights
- Market Performance: Corona continues to be the fastest growing company among top 30 companies of Indian Pharmaceutical Market (IPM) for last 6 consecutive months, as per MAT June'26
- Market Outperformance: Company outperformed market by 1.9 times as per MAT June'26
- Rank Improvement: Market rank moved 3 places up in a year to 26th Rank as per MAT June'26 (from 29th Rank as of MAT June'25)
- Therapy Leadership: Company stands at 5th rank in Gynaecology therapy segment
Strategic Developments
- New Manufacturing Facility: Inaugurated and initiated commercialization of EU-GMP approved Female Hormone Manufacturing Facility based in Ahmedabad on June 30, 2026
- Brand Integration: Initiated smooth integration of Wokadine (acquired brand) from supply side and distribution perspective
Management Commentary
Mr. Nirav K. Mehta, Managing Director & CEO, commented on the performance:
"Q1 FY27 shows our commitment to consistent growth with operational excellence and brand building. With robust revenue growth and market rank improvement, we see positive outcomes of the strategies in place.
We aim to move steadfast with our aligned focus on core therapies such as Women's Healthcare, Cardio-diabetes, Pain Management and Urology. We are also strengthening ourselves in Infertility and Biosimilar segment."